Single-Dose Pharmacokinetics Of Pediatric And Adult Formulations Of Etravirine And Swallowability Of The 200-Mg Tablet: Results From Three Phase 1 Studies

Objectives: Three studies were conducted to assess the pharmacokinetics, methods of administration and ease of swallowability of etravirine tablets. Methods: Two randomized studies in healthy adults investigated the single-dose pharmacokinetics of etravirine in various dosage strengths and the effects of dispersion in water and film-coating. A third study explored swallowability of etravirine 200-mg tablets in HIV-infected patients. First study: 37 volunteers received 1 x 100-mg non-coated tablet (reference), 4 x 25-mg non-coated tablets and 1 x 100-mg non-coated tablet dispersed in 100 ml water. Second study: 24 volunteers received 2 x 100-mg non-coated tablets (reference), 2 x 100-mg coated tablets, 1 x 200-mg non-coated and 1 x 200-mg coated tablet. Pharmacokinetic parameters were determined using non-compartmental analysis and least square means (LSM) ratios and 90% confidence intervals (CI) were calculated. Third study: 49 virologically-suppressed patients already on an etravirine-containing regimen rated the swallowability of two etravirine formulations (200-mg non-coated and 200-mg coated tablets). Results: In the first study LSM ratios (90% CI) for the etravirine area under the plasma concentration-time curve (AUC) administered either as 4 x 25-mg tablets or 100-mg tablet dispersed were: 0.91 (0.85 to 0.98) and 0.97 (0.90 to 1.03), respectively. In the second study, when comparing a 200-mg non-coated and coated tablet to 2 x 100-mg non-coated tablets, LSM ratios for etravirine AUC were 98 to 99%. In the third study, more patients rated the 200-mg than the 100-mg tablets as acceptable to swallow (70% vs. 43%). Conclusions: Comparable etravirine exposures were observed regardless of formulation or method of administration (i.e., dispersion); 200-mg tablets were rated as easier to swallow than 100-mg tablets.